Methylphenidate in ADHD With Trichotillomania
Recruitment status was Recruiting
This study will evaluate the safety and effectiveness of methylphenidate in treating attention deficit hyperactivity disorder (ADHD) in children with both ADHD and trichotillomania.
Trichotillomania is an impulse control disorder. There is growing evidences of the involvement of dopaminergic neurotransmission in the pathophysiology of trichotillomania. Reported increase in the prevalence of ADHD among patients with impulse control disorders, such as pathological gambling as well as trichotillomania, may result from the overlapping pathophisiological background. It is hypothesized that in cases of ADHD comorbid with trichotillomania methtylphenidate treatment will exhibit beneficial effects in both the ADHD and the hair pulling.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Methylphenidate Treatment of Children and Adolescents Diagnosed With ADHD and Its Influence on Comorbid Trichotillomania|
- Clinicial administered Massachusetts General Hospital Hair Pulling Scale for trichotillomania [ Time Frame: First 6 weeks of treatment ]
- Clinicial administered ADHD Rating Scale Clinical Global Impressions (CGI) scale for ADHD severity Weekly spontaneous self report of side effects [ Time Frame: Within the first 6 weeks of treatment ]
|Study Start Date:||October 2007|
|Estimated Study Completion Date:||October 2009|
Thirty children and adolescents aged 6-18 years, diagnosed with ADHD and trichotillomania, will receive MPH monotherapy treatment for a period of 12 weeks, targeting both ADHD and trichotillomania symptoms as rated by the ADHD- rating scale (ADHD-RS) and by the Massachusetts General Hospital Hair Pulling Scale and Clinical Global Impression-Severity (CGI) scale. The rating scales will be assessed at baseline and at the endpoint (after 12 weeks).The side effects will be monitored via weekly spontaneous self reports by each participant. All results will be expressed as mean ±SD. Student's paired t-test and ANOVA test will be used as appropriate.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00552266
|Contact: Pavel Golubchik, M.D.||+firstname.lastname@example.org|
|Geha Mental Health Center||Recruiting|
|Petah Tikva, Israel, 49100|
|Principal Investigator:||Pavel Golubchik, M.D.||Geha Mental Health Center|